Transgenic mice with SERT overexpression were more susceptible to pulmonary hypertension [104], and administering SERT inhibitors prevented hypoxia-induced pulmonary vascular remodeling in wild-type animals [105]. Here, SLC6A4 is linked to pulmonary arterial hypertension.